



Australian Government

Department of Health, Disability and Ageing
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:		211661	BLACKMORES COQ10 150mg
ARTG entry for	Medicine Listed		
Sponsor	Blackmores Ltd		
Postal Address	PO Box 1725, WARRIEWOOD, NSW, 2102 Australia		
ARTG Start Date	2/07/2013		
Product Category	Medicine		
Status	Active		
Approval Area	Listed Medicines		

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . BLACKMORES COQ10 150mg

Product Type	Single Medicine Product	Effective Date	2/10/2025
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps reduce/decrease free radical damage to body cells
Maintain/support energy levels
Helps in the maintenance of healthy blood lipids/blood fats
Maintain/support cardiovascular system health
Maintain/support healthy cardiovascular system function
Maintain/support heart health
Maintain/support blood vessel health
Helps enhance/promote blood vessel health
Maintain/support (state vitamin/mineral/nutrient) levels in the body

Indication Requirements

Product presentation must not imply or refer to lowering blood lipids, blood fats and triglycerides.
Product presentation must not imply or refer to serious cardiovascular conditions.
Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.
Product presentation must not imply or refer to chronic fatigue syndrome.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Do not take while on warfarin therapy without medical advice.

Additional Product information

Pack Size/Poison information



Australian Government
Department of Health, Disability and Ageing
Therapeutic Goods Administration

Pack Size	Poison Schedule
Components	
1 . Formulation 1	
Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	
Active Ingredients	
ubidecarenone	150 mg
Other Ingredients (Excipients)	
Gelatin	
glycerol	
hydrogenated vegetable oil	
iron oxide black	
iron oxide red	
lecithin	
medium chain triglycerides	
purified water	
Soya Oil	
yellow beeswax	

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary